Department of Oncology, MRC Oxford Institute for Radiation Oncology, University of Oxford, Headington OX3 7DQ, UK.
Biomolecules. 2021 Oct 29;11(11):1604. doi: 10.3390/biom11111604.
Tumour hypoxia is significantly correlated with patient survival and treatment outcomes. At the molecular level, hypoxia is a major driving factor for tumour progression and aggressiveness. Despite the accumulative scientific and clinical efforts to target hypoxia, there is still a need to find specific treatments for tumour hypoxia. In this review, we discuss a variety of approaches to alter the low oxygen tumour microenvironment or hypoxia pathways including carbogen breathing, hyperthermia, hypoxia-activated prodrugs, tumour metabolism and hypoxia-inducible factor (HIF) inhibitors. The recent advances in technology and biological understanding reveal the importance of revisiting old therapeutic regimens and repurposing their uses clinically.
肿瘤缺氧与患者的生存和治疗结果密切相关。在分子水平上，缺氧是肿瘤进展和侵袭性的主要驱动因素。尽管在科学和临床方面都在努力针对缺氧，但仍然需要寻找针对肿瘤缺氧的特定治疗方法。在这篇综述中，我们讨论了各种改变低氧肿瘤微环境或缺氧途径的方法，包括碳氧呼吸、热疗、缺氧激活前药、肿瘤代谢和缺氧诱导因子（HIF）抑制剂。最近在技术和生物学理解方面的进展表明，重新审视旧的治疗方案并在临床上重新利用它们的用途非常重要。
